Though there are concerns about the potential for carcinogenesis with the use of GLP-2 or its analogues [89] and further studies are needed, GLP2 analogues such as teduglutide might be an attractive approach for clinical treatment of NAFLD/NASH through structural and functional restoration of the intestinal epithelium, which would presumably reduce both intestinal permeability and endotoxemia. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.